Drug Trial Radar · NCT01103635
Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma
Last checked: Nov 19, 2026Latest source record: Apr 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
25
Actual
Start
Feb 2010
Primary completion
May 2016
Study completion May 2, 2016
Sponsor
- Lead sponsor
- Abramson Cancer Center at Penn MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 14, 2010
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Monoclonal antibodies, such as tremelimumab and CD40 agonist monoclonal antibody CP-870,893, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry cancer-killing substances to them. Giving tremelimumab together with CD 40 agonist monoclonal antibody CP-870, 893 may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of giving tremelimumab together with CD40 agonist monoclonal antibody CP-870,893 in treating patients with metastatic melanoma.
Conditions
- Recurrent Melanoma
- Stage IV Melanoma
Interventions
CD40 agonist monoclonal antibody CP-870,893Biological
Given IV
tremelimumabBiological
Given IV
laboratory biomarker analysisOther
Correlative studies
Primary outcomes
What the sponsor says the trial is designed to measure.
- Toxicity as assessed by CTCAE v3.0Time frame: 2 years
- ResponseTime frame: 2 years
- Immunological outcomes (analysis of antigen presenting cell activation, antigen-specific T cells, and tumor-specific T cells)Time frame: 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Abramson Cancer Center of The University of Pennsylvania
Philadelphia, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.